Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Engineered hyaluronic acid hydrogel for enhanced EV retention and controlled release

Ziel

Extracellular vesicles (EVs) are rapidly emerging as a next-generation therapeutic modality in regenerative medicine and immunomodulation. However, a major translational limitation is their rapid dispersion and clearance following administration. Existing hydrogel delivery systems typically rely on physical encapsulation in gels developed for other biomedical applications, or chemical/ genetic modification of EVs to tether them to hydrogels to achieve retention. Such approaches lack control over EV release, or can alter EV surface properties, complicate manufacturing, and restrict compatibility to specific EV types. To address this problem, GelEV aims to validate a novel hyaluronic acid (HA)-based hydrogel that enhances EV retention without requiring EV surface modification or encapsulation. This bio- and cyto-compatible platform incorporates hydrogel modifications to prolong local EV availability while preserving native EV structure and function. By avoiding EV modification steps, the system is designed to be compatible with diverse EV sources and manufacturing pipelines. Thus far, this novel hydrogel demonstrates increased retention of murine MSC-derived EVs. This project will de-risk the technology by verifying hydrogel manufacturability and by validating compatibility with clinically relevant human, lyophilised, and commercially available EV formulations. Functional assays will confirm preservation of bioactivity following sustained release. The development of an EV-agnostic hydrogel delivery platform will create an enabling technology for the expanding EV therapeutics sector. If successful, the licensable platform will allow EV developers to enhance therapeutic performance by having a controlled EV delivery tool, without altering their EV products, thereby accelerating clinical translation across multiple regenerative and inflammatory indications for patients, positioning it for commercial adoption in research and pharmaceutical contexts.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

UNIVERSITY OF GALWAY
Netto-EU-Beitrag
€ 150 000,00
Adresse
UNIVERSITY ROAD
H91 Galway
Irland
Region
Ireland Northern and Western West
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Begünstigte (1)